Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole (Q39420822)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole (English)

1 reference

Europe PubMed Central

11 September 2017

(RS)-rabeprazole

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

S Sahara

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Sugimoto

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

T Uotani

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

H Ichikawa

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Yamade

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Iwaizumi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

T Yamada

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

K Sugimoto

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

K Umemura

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

H Miyajima

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

T Furuta

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

0 references

publication date

16 September 2013

1 reference

Europe PubMed Central

11 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

38

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1129-1137

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24099474%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

The role of antisecretory drugs in the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Proton pump inhibitors--differences emerge in hepatic metabolism

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

The life and death of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12492

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39420822&oldid=1826797242"